Back to search
HR 6433 - 112

FDA User Fee Corrections Act of 2012

Became Public Law No: 112-193.

Bill highlights

Votes, text signals, source context, and latest movement from this record.

Bill Text Stats

4
Analyzed sections
N/A
Detected dollar total
0
Tax signals
2
Deadlines

Signal counts

Tax density 0.0%
Spending density 0.0%
Statutory Reference 8
Amendments 3
Deadline 2
Fees 2

Top agencies

N/A

Statutory references

21 USC 379j-42 2
21 USC 301 1
21 U.S.C. 352 1
21 U.S.C. 379f 1
21 USC 379j 1
21 U.S.C. 379j-42 1
Public Law 112-193 1

House Votes

No House roll call votes have been linked to this bill yet.

Timeline

Oct 5, 2012

Signed by President.

Oct 5, 2012

Signed by President.

Oct 5, 2012

Became Public Law No: 112-193.

Oct 5, 2012

Became Public Law No: 112-193.

Sep 25, 2012

Presented to President.

Sep 25, 2012

Presented to President.

Sep 24, 2012

Message on Senate action sent to the House.

Sep 22, 2012

Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(consideration: CR 9/21/2012 S6671)

Sep 22, 2012

Passed Senate without amendment by Unanimous Consent. (consideration: CR 9/21/2012 S6671)

Sep 20, 2012

Received in the Senate, read twice.

Sep 19, 2012

Introduced in House

Sep 19, 2012

Introduced in House

Sep 19, 2012

Referred to the House Committee on Energy and Commerce.

Sep 19, 2012

Committee on Energy and Commerce discharged.

Sep 19, 2012

Committee on Energy and Commerce discharged.

Sep 19, 2012

Mr. Upton asked unanimous consent to discharge from committee and consider.

Sep 19, 2012

Considered by unanimous consent. (consideration: CR H6137-6138)

Sep 19, 2012

Passed/agreed to in House: On passage Passed without objection.(text: CR H6137-6138)

Sep 19, 2012

On passage Passed without objection. (text: CR H6137-6138)

Sep 19, 2012

Motion to reconsider laid on the table Agreed to without objection.

Affected Sectors

How to read this

Sectors are deterministic matches from official Congress.gov data and cached bill text. They are source-derived signals, not conclusions about intent or economic effect.

Evidence matches count official fields, normalized subjects, cached text snippets, or extracted entities that matched the sector rules.

Impact is a bill-level rollup used for sorting and filtering. It is not an economic impact estimate.

Confidence is the strongest individual match score behind that sector.

Evidence snippets show why a sector matched and can repeat when Congress.gov repeats the same phrase across official fields.

Healthcare
3 evidence matches
Impact 100% Confidence 90%

Health

FDA User Fee Corrections Act of 2012 Became Public Law No: 112-193. Health

ongress Public Law 193] [From the U.S. Government Publishing Office] [[Page 126 STAT. 1443]] Public Law 112-193 112th Congress An Act To make corrections with respect to Food and Drug Administration user fees. NOTE: Oct. 5, 2012 - [H.R. 6

CBO Cost Estimates

Official Congressional Budget Office cost estimate links associated with this bill through Congress.gov records.

How to read this

CBO estimates are official source documents with their own assumptions, scope, and publication dates. They can score a bill, a version of a bill, or a broader legislative package.

LawLinter stores the source link from Congress.gov and does not replace the CBO document. Use these cards as pointers for source review, not as independent fiscal advice.

CBO context shows source-attributed Congressional Budget Office cost estimates linked from official Congress.gov bill records. It is research context only; read the official CBO source document for assumptions, scope, and dates.

No CBO cost estimate is currently linked for this bill.

Campaign Finance Context

Related FEC/OpenFEC campaign-finance records for lawmakers and candidates tied to this bill through source-attributed legislative relationships. These are not donations to the bill itself.

How to read this

Amounts shown here are campaign-finance totals for sponsor or cosponsor-linked candidates and their committees in the displayed FEC cycle.

They are not donations to this bill, spending on this bill, or proof that money influenced or caused sponsorship, cosponsorship, votes, or legislative outcomes.

If multiple linked lawmakers have FEC records, this section can show multiple candidate cards and separate sponsor/cosponsor rollups.

Campaign-finance context uses source-attributed FEC/OpenFEC records that are related or relevant to the displayed bill, lawmaker, candidate, committee, or legislative relationship through deterministic links. It is research context only, not proof of influence, causation, endorsement, or that money caused a sponsorship, vote, or legislative outcome.

No FEC/OpenFEC campaign-finance context is currently linked for this bill.

Lobbying Context

Related LDA.gov filings where public lobbying activity descriptions reference this bill. These records are source-attributed research context, not evidence of influence or causation.

How to read this

LDA filings are public lobbying disclosure records. LawLinter links them here only when the filing activity text contains an exact-looking reference to this bill.

A filing can mention many issues, clients, agencies, or bills. A match should be treated as a pointer for review, not as a conclusion about why legislation changed or how any lawmaker acted.

Lobbying context uses source-attributed LDA.gov records that appear related to this bill through bill references in public lobbying activity descriptions. It is research context only, not proof of influence, causation, endorsement, lobbying effectiveness, or legislative intent.

No LDA.gov lobbying disclosure context is currently linked for this bill.

Summary

49 Public Law Nov 9, 2012

(This measure has not been amended since it was introduced. The summary of that version is repeated here.) FDA User Fee Corrections Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA), as amended by the Food and Drug Administration Safety and Innovation Act (P.L. 112-144), to: (1) make clerical corrections to provisions of such Act; and (2) eliminate the restriction that appropriated funds shall be available only for payment of increases in the cost of reviewing medical device applications, including related personnel costs. Specifies due dates in FY2013 under FFDCA for the drug master file fee, the abbreviated new drug application and prior approval supplement filing fees, and the generic drug facility and active pharmaceutical ingredient facility fees.

00 Introduced in House Nov 9, 2012

FDA User Fee Corrections Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA), as amended by the Food and Drug Administration Safety and Innovation Act (P.L. 112-144), to: (1) make clerical corrections to provisions of such Act; and (2) eliminate the restriction that appropriated funds shall be available only for payment of increases in the cost of reviewing medical device applications, including related personnel costs. Specifies due dates in FY2013 under FFDCA for the drug master file fee, the abbreviated new drug application and prior approval supplement filing fees, and the generic drug facility and active pharmaceutical ingredient facility fees.

Sponsors

Amendments

No amendment records are currently available for this bill.
Compiled bill record. Bill pages combine Congress.gov source payloads, normalized relationships, cached text analysis, vote links, and deterministic sector/signal extraction. This is not an official government record or legal advice; use the official source link when accuracy matters.